VICTORIA, BC, Sept. 30, 2014 /CNW/ - T-Bird Pharma Inc.
(TSXV:TPI) ("T-Bird" or the "Company"), a
pharmaceutical company focused on developing premium quality
medical marijuana products, is pleased to announce that it has
retained Pure Advertising & Marketing Inc. ("Pure") to provide
investor relations services on behalf of the Company.
Pure is an established venture capital advisory firm based in
Vancouver, BC and has successfully
demonstrated the ability to work with junior companies in
articulating a company's inherent value to the investment community
and strategic partners.
The Agreement is for a term of eighteen months and may be
terminated by either party by giving 90 days' written notice of
such termination. The Company will pay a monthly retainer fee to
Pure of $7,500 plus HST and any
reasonable pre-approved expenses incurred on behalf of the Company.
The Company has also granted Kam
Thindal, the sole shareholder of Pure, 300,000 incentive
options to purchase shares of the Company. The options will
follow the guidelines set out in the Company's stock option plan
and as set forth by TSX Venture Exchange policy. The investor
relations agreement, options and option pricing are subject to the
approval of the TSX Venture Exchange.
About Pure
Pure is owned by Mr. Kam
Thindal. The firm works with junior public and private
emerging companies to provide capital markets advisory and capital
raising services in a variety of industries and
sectors.
About T-Bird and Thunderbird
Thunderbird Biomedical Inc. is a British Columbia private company incorporated
under the BCBCA on January 28, 2013,
and is wholly-owned by T-Bird Pharma Inc. The principal
activities of Thunderbird are the production of marijuana from its
Victoria, British Columbia
production facility, as regulated by the Marihuana for Medical
Purposes Regulations (Canada). Thunderbird obtained a
medical marijuana license to undertake the production of medical
marijuana in February 2014, being the
fifth company in Canada to obtain
such a license. T-Bird is the publically traded parent
company of Thunderbird.
ON BEHALF OF THE BOARD
"Robert Gagnon"
CEO and Director
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Cautionary Statements Regarding Forward Looking
Information
Certain statements in this press release constitute
forward-looking statements, within the meaning of applicable
securities laws. All statements that are not historical
facts, including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements".
We caution you that such "forward-looking statements" involve
known and unknown risks and uncertainties that could cause actual
and future events to differ materially from those anticipated in
such statements.
Forward-looking statements include, but are not limited to,
statements with respect to commercial operations, including
production and sales of medical marijuana, anticipated revenues,
projected size of market, quantities of future medical marijuana
production, completion of production facilities and other
information that is based on forecasts of future results, estimates
of amounts not yet determinable and assumptions of
management.
T-Bird Pharma Inc. (the "Company") does not intend, and
does not assume any obligation, to update these forward-looking
statements except as required by law. These forward-looking
statements involve risks and uncertainties relating to, among other
things, results of production and sale activities, the Company's
historical experience with medical marijuana operations, uninsured
risks, regulatory changes, availability of production facilities,
timeliness of government approvals and the granting of permits and
licenses, changes in prices, actual operating and financial
performance of facilities, equipment and processes relative to
specifications and expectations. Actual results may differ
materially from those expressed or implied by such forward-looking
statements.
SOURCE T-Bird Pharma Inc.